Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety ...

Counterfeit forms of weight loss and diabetes drugs are endangering consumers, and Oklahoma General Attorney Gentner Drummond wants to take action against what he calls "bad actors" in the ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

While RYBELSUS offers an oral version of semaglutide approved for improving glycemic control in adults with type 2 diabetes ... Also, a shorter titration schedule may facilitate a quicker onset ...

While Rybelsus offers an oral version of semaglutide approved for improving glycemic control in adults with type 2 diabetes ... Also, a shorter titration schedule may facilitate a quicker onset ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro ... Nordisk's GLP-1 agonist Ozempic (semaglutide), a key competitor.

Originally developed for diabetes management ... The “trendification” of Ozempic and semaglutide is putting immense pressure on supply chains and creating a dangerous vacuum – one that's ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).